More on the CRISPR patent matter

IPBiz has been covering the patent issues with CRISPR (e.g.,
Will there be an interference between the Zhang and Doudna work on CRISPR? ;
CRISPR is high profile in science, patents; competitor labeled a mere second comer )

Further to IPBiz posts on the CRISPR matter, note

http://www.utahpeoplespost.com/2015/05/gene-editing-tech/

UPDATE on 22 July 2015

Note the text: On the other hand, a third party has filed documentation in support of a claim against the Doudna application for failure to comply with the duty of candor and good faith, which encompasses the duty to disclose prior art; thus, invalidating any patent that might issue from the Doudna application.

A finding of inequitable conduct renders the claims of the associated patent unenforceable, not invalid.


http://www.iplawalert.com/2015/07/articles/patent/crispr-technology-a-first-to-invent-dispute-in-a-now-first-inventor-to-file-patent-regime/